|
Evaluation of patients with a clinical diagnosis of the amnesic variant of Alzheimer´s disease phenotype without specific treatment. |
|
Anti-PD1 2C12 in patients with relapsed or refractory Hodgkin lymphoma |
|
Ozonized platelet-rich plasma and ozonized platelet-rich fibrin in temporomandibular osteoarthritis. Fase II |
|
Effect of continuous slow renal replacement therapies in the treatment of acute kidney injury in critically ill patients. |
|
Policosanol on cognitive impairment after ischemic stroke |
|
Effectiveness and Safety of Jusvinza in Patients with Chikungunya |
|
Growth hormone-releasing peptide in sepsis-induced myocardial dysfunction. |
|
Effectiveness of a multicomponent focalized hotspot targeted strategy to reduce dengue transmission |
|
Evaluation of the effect of the SymBiElle for vaginal health |
|
Policosanol in Coronary Artery Disease |
|
HeberNasvac in chronic hepatitis B viral infection in adult patients. Routine clinical practice study |
|
Efficacy and safety of CIMAvax-FOLFOX-BEVA in unresectable, left-sided, metastatic, colorectal cancer. Phase I/II |
|
Rectal ozone therapy in patients with joint symptoms following the acute phase of Chikungunya. |
|
Evaluation of the possible protective effect of Curmeric on the clinical evolution of patients in the post-acute and chronic period of Chikungunya disease |
|
Safety and therapeutic effect of administration of Jusvinza in the post-acute stage of Chikungunya infection |
|
Safety and therapeutic effect of administration of Jusvinza in the chronic stage of Chikungunya infection |
|
Anti-PD1 2C12 in adult patients with advanced non-small cell lung cancer and unresectable or metastatic melanoma. Phase I-II |
|
Evaluation of the satiating and probiotic effect of goat cheese in volunteers on a weight control regimen: A randomized controlled trial |
|
Efficacy and safety of the monoclonal antibody nimotuzumab plus FOLFOX vs. FOLFOX as first-line treatment of patients with unresectable, left-sided, metastatic colorectal cancer. Phase I/II |
|
Evaluation of safety and tolerability of JM-20 with healthy volunteers. Clinical trial Phase I. |
